Kangtai Biotech: The novel coronavirus inactivated vaccine independently developed by the company is included in emergency use
Kangtai Biotech announced that the novel coronavirus inactivated vaccine independently developed by the company is used to prevent epidemic diseases caused by the novel coronavirus infection and belongs to Class 1.1 of preventive biological products. The novel coronavirus inactivated vaccine completed phase I and II clinical trials in February 2021. At present, the company has begun work related to phase III clinical trials of the novel coronavirus inactivated vaccine. The company's novel coronavirus inactivated vaccine is now included in emergency use. If it is subsequently procured and used on a large scale by relevant national departments, it will have a positive impact on the company's business performance and further enhance the company's core competitiveness.
$Shenzhen Kangtai Biological Products(300601.SZ$
$Shenzhen Kangtai Biological Products(300601.SZ$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Twitter@Sino_Market | Realtime Chinese market info provider.
9359Followers
4Following
8855Visitors
Follow